PDF(Pubmed)
Abstract：
UNASSIGNED: There is a great need to find alternative treatments for chronic pain which have become a healthcare problem. We discuss current therapeutic targeting Nav1.7.
UNASSIGNED: Nav1.7 is a sodium ion channel protein that is associated with several human pain genetic syndromes. It has been found that mutations associated with Nav1.7 lead to the loss of the ability to perceive pain in individuals that are otherwise normal. Several therapeutic interventions are presently undergoing preclinical and research using the methodology of damping Nav1.7 expressions as a methodology to decrease the sensation of pain leading to analgesia.
UNASSIGNED: It is our strong belief that there is a viable future in the targeting of protein of Nav1.7 for the relief of chronic pain in humans. The review will look at the genomics associated with SCN1A and proteomic of Nav1.7 as a foundation to explain the mechanism of the therapeutic interventions targeting Nav1.7, the human disease that are associated with Nav1.7, and the current development of treatment for chronic pain whether in preclinical or clinical trials targeting Nav1.7 expressions. The development of therapeutic antagonists targeting Nav1.7 could be a viable alternative to the current treatments which have led to the opioid crisis. Therefore, Nav1.7 targeted treatment has a major clinical significance that will have positive consequences as it relates to chronic pain interventions.
UNASSIGNED: Nav1.7 is a sodium ion channel protein that is associated with several human pain genetic syndromes. It has been found that mutations associated with Nav1.7 lead to the loss of the ability to perceive pain in individuals that are otherwise normal. Several therapeutic interventions are presently undergoing preclinical and research using the methodology of damping Nav1.7 expressions as a methodology to decrease the sensation of pain leading to analgesia.
UNASSIGNED: It is our strong belief that there is a viable future in the targeting of protein of Nav1.7 for the relief of chronic pain in humans. The review will look at the genomics associated with SCN1A and proteomic of Nav1.7 as a foundation to explain the mechanism of the therapeutic interventions targeting Nav1.7, the human disease that are associated with Nav1.7, and the current development of treatment for chronic pain whether in preclinical or clinical trials targeting Nav1.7 expressions. The development of therapeutic antagonists targeting Nav1.7 could be a viable alternative to the current treatments which have led to the opioid crisis. Therefore, Nav1.7 targeted treatment has a major clinical significance that will have positive consequences as it relates to chronic pain interventions.
摘要：
■非常需要找到已成为医疗保健问题的慢性疼痛的替代疗法。我们讨论了当前的治疗靶向Nav1.7。
■Nav1.7是一种与几种人类疼痛遗传综合征相关的钠离子通道蛋白。已经发现,与Nav1.7相关的突变导致在原本正常的个体中感知疼痛的能力丧失。目前正在使用抑制Nav1.7表达的方法进行临床前和研究，以减少导致镇痛的疼痛感觉。
■我们坚信，靶向Nav1.7蛋白以缓解人类慢性疼痛是可行的。这篇综述将着眼于与SCN1A相关的基因组学和Nav1.7的蛋白质组学，作为解释针对Nav1.7的治疗干预机制的基础，与Nav1.7相关的人类疾病，以及慢性疼痛治疗的当前发展无论是临床前还是针对Nav1.7表达的临床试验。针对Nav1.7的治疗性拮抗剂的开发可能是导致阿片类药物危机的当前治疗的可行替代方案。因此,Nav1.7靶向治疗具有重要的临床意义，这将具有积极的后果，因为它涉及慢性疼痛干预。
■Nav1.7是一种与几种人类疼痛遗传综合征相关的钠离子通道蛋白。已经发现,与Nav1.7相关的突变导致在原本正常的个体中感知疼痛的能力丧失。目前正在使用抑制Nav1.7表达的方法进行临床前和研究，以减少导致镇痛的疼痛感觉。
■我们坚信，靶向Nav1.7蛋白以缓解人类慢性疼痛是可行的。这篇综述将着眼于与SCN1A相关的基因组学和Nav1.7的蛋白质组学，作为解释针对Nav1.7的治疗干预机制的基础，与Nav1.7相关的人类疾病，以及慢性疼痛治疗的当前发展无论是临床前还是针对Nav1.7表达的临床试验。针对Nav1.7的治疗性拮抗剂的开发可能是导致阿片类药物危机的当前治疗的可行替代方案。因此,Nav1.7靶向治疗具有重要的临床意义，这将具有积极的后果，因为它涉及慢性疼痛干预。
